Breast Cancer

This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer.

The phase 3 study LORELEI compared neoadjuvant therapy with letrozole plus placebo versus letrozole plus taselisib, a PI3K inhibitor, in this patient population.“

Treatment with a regimen of pembrolizumab plus trastuzumab in patients with trastuzumab-resistant advanced HER2-positive breast cancer was well-tolerated and had clinical benefit in those whose tumors were positive for a biomarker for pembrolizumab.
Patients aged 40 years with breast cancer who underwent axillary lymph node dissection were more likely to experience arm swelling and decreased range of arm motion than patients who received less invasive sentinel lymph node biopsies.
According to the results of 2 recent analyses, dose-dense or dose-intense chemotherapy reduces the risk for breast cancer recurrence and improves survival compared with standard chemotherapy regimens.
In patients with HR-positive breast cancer, a positive circulating tumor cells assay result was associated with nearly a 20-fold increased risk for recurrence of disease.
Older women with hormone receptor–positive, HER2-negative metastatic breast cancer who are treated with a CDK4/6 inhibitor may derive benefits similar to those seen in their younger counterparts.
At 10-year follow-up, investigators observed similar outcomes with exemestane alone and sequential tamoxifen/exemestane in the phase 3 TEAM trial of postmenopausal women with hormone receptor (HR)-positive early breast cancer.
The results of a recent gene-sequencing analysis identify new pathogenic mutations associated with an increased risk for breast cancer.
The extended use of anastrozole for 3 years beyond 5 years of sequential therapy did not improve disease-free survival or overall survival in postmenopausal women with hormone receptor–positive, early breast cancer.
Page 1 of 17
Results 1 - 10 of 168